The National Institutes of Health (NIH) is offering a federal grant opportunity titled "The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers," aimed at advancing research in inflammatory bowel disease (IBD). This initiative seeks to establish up to seven Genomic Research Centers that will leverage patient cohorts, biospecimens, and data science to explore genetic, clinical, and environmental factors influencing IBD, with the goal of developing new predictors for disease outcomes and enhancing precision medicine for patients. The total estimated funding for this program is $6.4 million, with nine awards expected to be granted, and interested applicants can reach out to Dr. Ludmila Pawlikowska at ludmila.pawlikowska@nih.gov or by phone at 301-480-9372 for further information. Key deadlines include an estimated synopsis post date of August 1, 2026, and a close date of November 1, 2026, with project start anticipated on July 1, 2027.

The National Institute of Diabetes and Digestive Diseases and Nutrition (NIDDK) seeks to advance its mission by continuing the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC). The IBDGC has led collaborative efforts resulting in the identification of &gt;300 genetic risk loci for different IBD subtypes across patient populations and characterization of underlying biological mechanisms. Despite advances in biological understanding and the development of a range of biologic therapies, IBD remains a chronic, severe and heterogenous disease with no cure requiring multiple interventions over the life course. Diagnostic biomarkers and accurate predictors of critical outcomes including disease remission, recurrence, and response to specific therapies are lacking. The IBDGC will leverage patient cohorts, biospecimens and advances in data science to characterize the interactions of genetic, clinical and environmental factors in disease development and progression, and to develop new predictors of disease outcomes, with the goal of improving medical management and advancing precision medicine for IBD patients. The IBDGC may include up to 7 Genomic Research Centers with varying research emphases, which will serve as sites for participant enrollment, molecular analysis of biospecimens and bioinformatics and computational analyses. 

Buyer

Eligible Applicants

Funding Category

Funding Instrument

Opportunity Category

Cost Sharing or Matching Requirement

Original Source